Trial Profile

In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol (Poly-ICLC): An Adaptive, Multicenter, Phase II Clinical Study

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Poly ICLC (Primary) ; Poly ICLC (Primary)
Indications Head and neck cancer; Malignant melanoma; Sarcoma; Solid tumours; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Oncovir

Most Recent Events

15 Dec 2020 Status changed from recruiting to completed.
11 Mar 2019 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
11 Mar 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2021.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com